- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Latest Conference Articles
Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer
February 21st 2025, 4:00pm
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC
February 20th 2025, 8:05pm
In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.
Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer
February 20th 2025, 4:00pm
ASCO Gastrointestinal Cancers Symposium
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.
Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status
February 20th 2025, 2:00pm
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC
February 19th 2025, 10:00pm
Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.
UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer
February 18th 2025, 10:00pm
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.
Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma
February 18th 2025, 2:00pm
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
February 17th 2025, 8:00pm
Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.
An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment
February 17th 2025, 5:00pm
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Treatment Intensification Adoption Differences Across Prostate Cancer
February 16th 2025, 7:00pm
There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.